|
|
Article: Glaxo Wellcome Inc. Receives Clearance to Market Amerge(TM) (Naratriptan Hydrochloride) Tablets in U.S.
- Article from:
- PR Newswire
- Article date:
- February 11, 1998
CopyrightCOPYRIGHT 1998 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Selective Therapy Useful in Long-Duration Migraine
RESEARCH TRIANGLE PARK, N.C., Feb. 11 /PRNewswire/ -- Glaxo Wellcome Inc. has received clearance from the United States Food and Drug Administration to market Amerge(TM) (naratriptan hydrochloride) Tablets, a new medication for the acute treatment of migraine.
Amerge is a selective 5-HT1 agonist designed specifically to treat migraine attacks. In clinical trials, 60-66% of patients with moderate to severe headache responded to Amerge 2.5 mg within four hours. Of the patients who had relief with the initial dose, 72-81% did not have recurrence of headache within 24 hours. Amerge may be ...